|
|
- Milo Hensley
- 6 years ago
- Views:
Transcription
1 I. DEFINITION This training under Kilimanjaro School of Pharmacy Industrial Pharmacy Teaching Unit (IPTU) is an Advanced Training Program in Drug Development, Drug Manufacturing, Regulatory & Quality Compliance. II. INTRODUCTION The purpose of this advanced training program is to provide in-depth level education/ training in the important aspects of Drug Development, Drug Manufacturing, Regulatory and Quality Compliance in the Pharmaceutical Industry. Thereby, participants/students will have an opportunity to improve their knowledge of drug development, drug manufacturing, regulatory and compliance issues and to explore careers in these exciting areas in the pharmaceutical industry or related institutions. The development of this program has been a joint effort between Purdue University, USA and Kilimanjaro School of Pharmacy - St. Luke Foundation, Tanzania. Individuals who successfully complete the advanced training program will be provided a certificate of completion signed jointly by Kilimanjaro School of Pharmacy - St. Luke Foundation and Purdue University. This advanced training program consists of four courses; each involves 45 contact hours as well as associated homework assignments and examinations. The certificate program consists of the following four courses: 1. Drug discovery, 2. Drug development and regulatory & quality compliance, 3. Drug manufacturing process, 4. Regulatory documents and generic drug approval submissions. Participants in the 2012 intake will complete the Industrial Pharmacy Advanced Training Program (all four courses)in two years. III. ELIGIBILTY Requirements: An applicant for this program must be a holder of at least a bachelor s degree in Pharmacy or Biochemistry, or Chemistry or Microbiology and Food technology industries. Participants: Applicants include persons employed in the pharmaceutical industry including positions in pharmaceutical manufacturing, pharmaceutical analysis, quality or regulatory affairs. Applications from qualified persons employed in universities looking to expand their curriculum or other public institutions such as medicines regulatory authorities are also welcome. V. APPLICATION PROCEDURE Applicants must complete the application form by 30 June 2012 for August 2012 intake. The application form is provided in the annex of this brochure, last page. Please send the completed form to: Kilimanjaro School of Pharmacy; IPTU, St. Luke Foundation P.O.BOX 481 MOSHI, TANZANIA. TEL/FAX: ; zekeocha@gmail.com Short-listed / selected applicants will be contacted through . Application fee of $50 (USD) to be paid by cheque or Bank draft; payable to Saint Luke Foundation, Deadline for the completed application form with fee to reach Saint Luke Foundation by 30 June 2012, for August 2012 in-take. 1
2 VI. COURSE DURATION & STARTING DATES For each course, the duration is 14 days. The program will begin with the courses as outline below: Drug discovery August 2012 Drug development, regulatory & quality compliance, March 2013 Followed by: Drug manufacturing process August 2013 Regulatory documents and generic drug approval submissions March 2014 VII. COURSE FEES AND COSTS Application fees 50 USD non refundable Registration fees 20 USD non refundable Tuition fees, materials and examination 1,500 USD 1,500 USD per course, excluding Application fee and Registration fee. Total for the program 6,000 USD Accommodation: For the duration of the courses SLF can Organise accommodation with half board Transportation from airport (arrival & departure for 50 USD per trip. Lunch will be provided at SLF at a rate of 10 USD per day. 2
3 VIII. COURSE CONTENTS The course contents shown can vary slightly at the discretion of the instructor to meet the requirements of students. Course 1: August 6 th 18 th 2012: Drug Discovery Lecture Number Module 1 Drug Discovery 2 Drug Discovery 3 Discovery Process 4 Discovery Biologists 5 Synthetic Chemistry 6 Discovery 7 Toxicology for Discovery 8 Drugs from Biotech 9 Early Formulations 10 Patents 11 Conclusion 12 Review and Exam Module 2 Early Development and Toxicology 1 Organization and Administration 2 Toxicology 3 Contract Research 4 Ethics 5 Phase I 6 Phase II 7 Marketing and Sales 8 Product Decisions 9 Clinical Trials 10 Clinical Trials 11 Clinical Trials 12 Case Study 13 Review and Conclusion 14 Exam Module 3 Chemistry Manufacturing and Controls 1 USP 2 Pisano 3 IND 4 DMF 5 End of Phase 2 6 Specifications 7 Impurities 8 Stability 9 Case Studies 10 Case Studies 11 FDA Structure 12 Submitting an NDA/IND 13 Review and Conclusion 14 Exam Course 2: March 2013 Drug development, Regulatory & Quality Compliance Module 1 - GMP Drug Product 1 Intro to GMP 2 GMP s Cleanliness and 3 Contamination Exercise 4 Six Systems-31 5 Six Systems Exercise 6 ICHQ1 7 ICHQ2 8 ICHQ3 9 ICHQ6 10 ICHQ8 11 ICHQ9 12 QC-QA 13 QC 14 GMP s. 3
4 15 GMP s as Learning Syst. 16 SUPAC - Changes Comparability Protocols 17 SUPAC Comparability Protocols - 18 Biologicals 19 USP for GMP 20 SOPs 21 SOP Example 22 OOS 23 Computer systems GMP s and Quality by 24 Design 25 KRMPAT-I 26 KRMPAT-II 27 Review and Conclusion 28 Exam Module 2 GMP API 2 GMP s 3 Systems & CAPA Module 3 - GLP 1 Quality 2 Toxicology 3 GDRPs 4 Information 5 Quality in Discovery 6 GLP 7 QC in Tox 8 IM Tox Archives 9 QA in Tox 9 Management 9 Furrow top Regulatory Facts 11 Role of Study Director In tox 12 FDA GLP Inspections 13 Exam Module 4 - GCP Quality and Compliance 1 Clinical Research 2 What goes wrong 3 RQA GCP - defective 4 RQA Auditing 5 QC in Clinical Res defective. 6 Reg. Aff. In Clin. Res. 7 FDA GCP Inspections 8 Pharmacovigilance Summary useful things - 9 delete 10 Exam 4
5 Course 3: August 2013: Drug Manufacturing Processes & Laboratory Module 1 Drug Product 2 Preformulation Principles 3 Dimensional Analysis 4 Powder Properties 5 Mechanical Properties 6 Particle Size Reduction 7 Blending 8 Blending 9 Granulation 10 Granulation 11 Drying 12 Tableting 13 Coating 14 Coating 15 Capsules 16 Aerosol Products 17 Aerosol Products 18 Parenterals 19 Parenterals 20 Parenterals Laboratory Modules to be conducted in the Industrial Pharmacy Teaching Unit. Module 2 API Manufacturing 2 Synthesis 3 Isolation 4 Crystallization 5 Drying 6 Impurities 7 Residual Solvents 8 Cert. of Analysis Module 3 Measurements 2 Crystallography 3 XRPD 4 IR & Raman 5 Chemical Imaging. 6 Particle Size 7 Mixture Analysis 8 Crystallization Module 4 Validation 2 Cleaning validation 3 Analytical Mtd. Validation 4 Computerized system valid. 5 Qualification Syst. & Equip. 6 Product & process valid. Granulation (T) Compression (T) Coating (T) Granulation (P) Compression (P) Dissolution Characterization 5
6 Course4: March 2014: Regulatory documents, generic drug approval submissions, quality, auditing Module 1 - ANDA 1 Application 2 Bioavailability 3 Validation of HPLC Method 4 Informed consent Components and 5 composition 6 Buildings and Facilities 7 Manufacturing 8 Controls 9 Methods Validation 10 Forced degradation 11 Dissolution validation Related substance 12 validation Module 2 ANDA 1 DP Specifications 2 Specifications exercise 3 Stability 4 Final Documents 5 QOS 6 Reg. Aff. In Clin. Res. 7 Exam Module 3 Auditing/Inspections 2 Role of Inspector 3 Prep. for Inspection 4 Types of Inspections 5 The Inspection 6 Audits 7 Internal Audits 8 Exam Quality by Design 1 Current vs. Desired State 2 Materials Properties 3 Prelim. Dev. Plan 4 Design Space 5 Important Areas for QbD 6 Sensors and Chemometrics 7 Impl. and Scale-up 8 QbD and Drug Subs. 9 Exam IX. COURSE COORDINATORS For questions on registration please contact: Sr. Zita A. Ekeocha Head Industrial Pharmacy Training Kilimanjaro School of Pharmacy Saint Luke Foundation P.O. Box 481, Moshi TANZANIA. zekeocha@gmail.com For questions regarding the curriculum please contact: Stephen R. Byrn, Ph.D Charles B. Jordan Professor of Medicinal Chemistry Department of Industrial & Physical Pharmacy Purdue University 575 Stadium Mall Drive West Lafayette, IN USA. sbyrn@pharmacy.purdue.edu Joseph M. Fortunak Associate Professor Chemistry and Pharmaceutical Sciences Howard University 525 College Street NW Washington, DC USA jfortunak@comcast.net <jfortunak@comcast.net> 6
7 ST. LUKE FOUNDATION KILIMANJARO SCHOOL OF PHARMACY When completed, return form to: Course Coordinator, Industrial Pharmacy Training, KSP, P.O BOX 481, Moshi. APPLICATION FOR ADMISSION TO THE INDUSTRIAL PHARMACY ADVANCED TRAINING PROGRAM Mr./Mrs./Ms. Surname Other names Date of Birth Nationality Home or Permanent Address Telephone Number Emergency contact (BPharm, BSc etc,) Institution, Date obtained Details of work experience: Qualifications Date Employer Position Nature of work No. of employees supervised: Briefly describe/list your daily responsibilities Do you have any physical or other disability requiring special arrangements or facilities YES/NO If YES, please forward to us further details of your disability and special requirements. I certify that the information given above is correct Signature Date: Statement of Support: Name of the Sponsor (Company, institution etc) purpose of training/ special training needs State I support the application of the candidate and certify that the information given by the candidate is correct. Signature Date: Please attach the agreement on continued employment for one year following the completion of the course to this application.
Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)
Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY!
More informationStability Studies for Pharmaceutical Products (API and finished products)
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry Stability Studies for Pharmaceutical Products (API and finished products)
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationCERTIFICATE IN BIOPHARMACEUTICALS
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN BIOPHARMACEUTICALS and GENERIC DRUGS Temple offers
More informationModern Validation Technology Boot Camp
2018 Modern Validation Technology Boot Camp Modern Process validation Risk based Modern cleaning Validation Facility and equipment qualification? Risk analysis Advanced Topics Protocols and SOPs 6700 TransCanada,
More informationNUSAGE PharmEng. Pharmaceutical and Biotechnology Training Program COMPUTERIZED SYSTEM VALIDATION
COMPUTERIZED SYSTEM VALIDATION NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry Objective COMPUTERIZED SYSTEM VALIDATION
More informationCMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.
CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways
More informationEFFECTIVE PROCESS VALIDATION NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Copyright 2014 NUSAGE-PharmEng.
EFFECTIVE PROCESS VALIDATION NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry EFFECTIVE PROCESS VALIDATION Objective
More informationProcess Validation for Active Pharmaceutical Ingredients (API)
National University of Singapore Academy of GxP Excellence (NUSAGE) and PharmEng Technology Presents Process Validation for Active Pharmaceutical Ingredients (API) Part of the Pharmaceutical and Biotechnology/Training
More informationEFFECTIVE CLINICAL TRIALS. NUSAGE PharmEng. Pharmaceutical and Biotechnology Training Program. Copyright 2014 NUSAGE-PharmEng.
EFFECTIVE CLINICAL TRIALS NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry EFFECTIVE CLINICAL TRIALS Objective The intent
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationProcess Analytical Technology (PAT)
National University of Singapore Academy of GxP Excellence (NUSAGE) & PharmEng Technology Presents Process Analytical Technology (PAT) Part of the Pharmaceutical and Biotechnology Training Courses Instructor
More informationA NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry EFFECTIVE PROCESS VALIDATION Instructor Rick Ng Date and Time 10-11
More informationWhen the FDA comes knocking, will your inspection be a success? YES
PRESENTED BY EDUQUEST IN COOPERATION WITH FDA COMPLIANCE BOOT CAMP 2017 I Auditing, Data Integrity, and Quality Systems GET FIVE DAYS OF HANDS-ON, INTERACTIVE TRAINING! YOUR INSTRUCTORS OCT. 16-20, 2017
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationEffective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)
Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! The globalization of the pharmaceutical
More informationAnalytical Method Validation
National University of Singapore Academy of GxP Excellence (NUSAGE) & PharmEng Technology Presents Part of the Pharmaceutical and Biotechnology Training Courses Instructor LOH Kean Chong, Ph.D.* Senior
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationCleaning Validation in Active Pharmaceutical Ingredient Manufacturing Plants
National University of Singapore Academy of GxP Excellence (NUSAGE) and PharmEng Technology Presents Cleaning Validation in Active Pharmaceutical Ingredient Manufacturing Plants Part of the Pharmaceutical
More informationPHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS
PHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS The document PHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS is intended to provide clarification on a number of issues that relate to Quality (e.g., Chemistry
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationTopics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities
Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,
More informationSenior Regulatory Affairs Executive AREAS OF EXPERTISE
Senior Regulatory Affairs Executive AREAS OF EXPERTISE More than fifteen years experience in vaccines, pharmaceuticals, biotechnology, and combination device products. Experience in regulatory strategy
More informationD.I.C.T - Data Integrity in Clinical Trials
D.I.C.T - Data Integrity in Clinical Trials How to secure global GMP- and GCP-compliant data governance Including Case Study: Data Integrity in Medical Imaging Studies New EMA Guideline on etmfs will come
More informationOverview Stability testing is an essential part of drug development which ensures the quality, safety and efficacy of the drug for the lifetime of the drug product. Appropriate storage conditions can only
More informationPharmaceutical cgmps for the 21st Century February 2004
Pharmaceutical cgmps for the 21st Century February 2004 Ludwig Huber Compliance Fellow for Life Sciences and Chemical Analysis Chairperson: Rob Sample FDA GxP Regulations Along the Drug Life Basic Research
More informationEffective Management and Operations of GXP Laboratories
Effective Management and Operations of GXP Laboratories Course Objective: Upon completion of this course, attendees involved in establishing and assuring that Good Laboratory / Good Manufacturing Practice
More informationUNIVERSITY OF MUMBAI
Academic Council 25/05/2011 Item No. 4.71 UNIVERSITY OF MUMBAI Syllabus for Clinical Studies Program: Diploma Course: Post Graduate Diploma in Clinical Studies, Data Management & Medical Writing (Introduced
More informationRegulations of Biologics in Taiwan
Regulations of Biologics in Taiwan Churn-Shiouh Gau, Ph.D. Executive Director, Taiwan 2013/2/13 1 Outlines Regulation of Drugs in Taiwan - Organizations Regulations for Marketing Approval for Drugs including
More informationANNEX. CHAPTER I General principles
ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More information2nd FDA/PQRI Conference on Advancing Product Quality
2nd FDA/PQRI Conference on Advancing Product Quality Generic Pharma Perspective on the Identification of Critical Quality Attributes and Critical Process Parameters Bruce D. Johnson, Ph.D. Vice President
More informationGMP meets Regulatory Affairs
Speakers: Marieke van Dalen Aspen Oss B.V., The Netherlands Dr Josef Hofer EXDRA GmbH, Germany Dr Usfeya A Muazzam Bonn, Germany Dr Rainer Gnibl EU-GMP Inspector, Bavarian Government GMP meets Regulatory
More informationa n d B i o s a fety C o n s i d e ra t i o n s
National University of Singapore Academy of GxP Excellence (NUSAGE) & PharmEng Technology Presents Good Laboratory Practices a n d B i o s a fety C o n s i d e ra t i o n s Part of the Pharmaceutical and
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationDECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW
DECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW 1.0 INTRODUCTION: The purpose of this guidance is to communicate the expectation with regard to the conduct of Product Quality Review. Product Quality
More informationEstablishing the Self Inspections and Controls for Ensuring Audits to Confirm Effective Laboratory Data Integrity, Data Integrity Controls,
Lab Data Integrity Meeting FDA & EU Concerns SPEAKERS: Dr Christopher Burgess Chairman of the ECA Analytical Quality Control Working Group Dr Bob McDowall Member of the ECA IT Compliance Interest Group
More informationProcess Validation. Instructor Philip K. Ngai, Ph.D.* Senior Advisor & Trainer. National University of Singapore Academy of GxP Excellence (NUSAGE)
National University of Singapore Academy of GxP Excellence (NUSAGE) & PharmEng Technology Presents Part of the Pharmaceutical and Biotechnology Training Courses Instructor Philip K. Ngai, Ph.D.* Senior
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer PART 1: GENERAL INFORMATION Name of Manufacturer Calyx Chemicals & Pharmaceuticals Ltd Unit:
More informationConducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development
Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality
More informationREPUBLIC OF MAURITIUS APPLICATION FOR REGISTRATION OF A DRUG
SCHEDULE Form 1 REPUBLIC OF MAURITIUS APPLICATION FOR REGISTRATION OF A DRUG THE REGISTRAR PHARAMCY BOARD MINISTRY OF HEALTH AND QUALITY OF LIFE MAURITIUS Fax: Telephone: TYPE OF APPLICATION HUMAN, BIOLOGICAL
More informationBest Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.
Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Specifications Breakout Session 2 Pete Yehl and Mike Coutant, moderators
More informationWhen the FDA comes knocking, will your inspection be a success? YES
PRESENTED BY EDUQUEST IN COOPERATION WITH FDA COMPLIANCE BOOT CAMP 2018 I Auditing, Data Integrity, and Quality Systems GET FIVE DAYS OF HANDS-ON, INTERACTIVE TRAINING! YOUR INSTRUCTORS MAY 14-18, 2018
More informationRegulations in Pharmaceutical Laboratories
Regulations in Pharmaceutical Laboratories February 2004 Ludwig Huber Compliance Fellow for Life Sciences and Chemical Analysis Chairperson: Rob Sample Regulations and Quality Standards Developed by Industries
More informationMINISTRY OF HEALTH ORDINANCE
MINISTRY OF HEALTH 1799 Pursuant to Article 73, paragraph 2, Article 74, paragraph 2 and Article 89, paragraph 2 of the Medicinal Products Act (Official Gazette 76/2013), the Minister of Health hereby
More informationGxP Auditing, Remediation, and Quality System Resourcing
GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing
More informationAn Introduction to Double Dragon Consulting
An Introduction to Double Dragon Consulting www.doubledragonconsulting.com 1 June 2012 About DDC Our Experience: All dosage forms, aseptic processes, OTC Remediation of 483 observations, warning letters,
More informationNUVISAN GROUP. Our Philosophy
NUVISAN GROUP Our Philosophy 2 EARLY DEVELOPMENT Introduction to Nuvisan Fully integrated Contract Research Organisation headquarted in Neu-Ulm, southern part of Germany. Nuvisan - Early Development Headquartered
More informationPerforming Multiple Regulatory Requirements within a Program Such as GMP, GLP, GCP, Medical Devices, and/or Controlled Substances
Performing Multiple Regulatory Requirements within a Program Such as GMP, GLP, GCP, Medical Devices, and/or Controlled Substances Performing Multiple Regulatory Requirements within a Program Such as GMP,
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationNatural Health Products Directorate (NHPD) Clinical Trial Application and Attestation for Instructions with Sunnybrook specifics
Appendix 4: Clinical Trial Application and Attestation Form Instructions Instruction sheet can be found online under Forms. The Clinical Trial Application and Attestation Form has 7 parts: Part 1: Applicant
More informationPHARMA KNOWLEDGE PARK
GUIDELINES 2013 WWW.NOORMD.COM A COMPILATION BY ON PHARMACEUTICAL REGULATORY GUIDELINES INTRODUCED / REVISED DURING THE YEAR 2013. Page 2 ICH Assessment and control of DNA reactive (mutagenic) impurities
More informationDate/Lecturer Class Topic Readings 01/28/10 Brookman
Course Director: Sheldon, Ph.D. 01/28/10 1 I. Course Description and Requirements II. Historical Perspectives and Overview of Drug Development a. Evolution of the pharmaceutical industry b. Changing development
More informationABB Industries PAT Validation
Alison Harrington ABB Industries PAT Validation ABB Industries - 1 - Topics PAT disciplines and framework FDA evolution PAT Regulatory Process Quality System Comparability Protocol Submission example Validation
More informationSetting Specifications and. Acceptance Criteria November 2015, Berlin, Germany ECA. Highlights:
ECA ACADEMY Speakers: Dr Thomas Fürst Boehringer Ingelheim Pharma, Dr Hiltrud Horn Horn Pharmaceutical Consulting, Dr Bettina Pahlen Quality x Pharma Consulting GmbH, Dr Wilhelm Schlumbohm Berlin, Dr Thomas
More informationYour Complete Quality Solution Provider for the Life Science Industry
Your Complete Quality Solution Provider for the Life Science Industry PQE at-a-glance Our broad services portfolio, extensive experience, effective project management, and exceptional cost effectiveness,
More informationICH Q 10 Pharmaceutical Quality System
National University of Singapore Academy of GxP Excellence (NUSAGE) and PharmEng Technology Presents ICH Q 10 Pharmaceutical Quality System Part of the Pharmaceutical and Biotechnology Training Courses
More informationA NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry STERILIZATION TECHNIQUES: STEAM & ETHYLENE OXIDE Instructor Dennis
More informationUnderstanding GxP (GMP, GCP & GLP) for FDA Regulated Industries
Microrite, Inc. brings you this unique learning experience in Understanding GxP (GMP, GCP & GLP) for FDA Regulated Industries; Part of Microrite s step-by-step webinar series. Understanding GxP (GMP, GCP
More informationCTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016
CTA/NDA Regulatory Landscape in China Jack Xie, PhD, DABT SOT 2016 Disclaimer The content of the following presentation represents solely author s view and may not reflect any position of Roche or China
More informationNatural Health Products Directorate (NHPD) Clinical Trial Application and Attestation for Instructions with Sunnybrook specifics
Appendix 4: Clinical Trial Application and Attestation Form Instructions Instruction sheet can be found online under Forms. The Clinical Trial Application and Attestation Form has 7 parts: Part 1: Applicant
More informationMedicines Control Authority of Zimbabwe
EFV... QUALITY INFORMATION SUMMARY (QIS) FOREWORD The Quality Information Summary (QIS) template should be completed to provide a condensed summary of the key quality information for product dossiers (PDs)
More informationGuidance on Requirements of the Sponsor and the Investigator as a Sponsor
Guidance on Requirements of the Sponsor and the Investigator as a Sponsor University of Colorado Denver (UCD) secures assurances from the sponsor or the investigator-sponsor* that the manufacture and formulation
More informationInternational Pharmaceutical Excipients Council Of The Americas
October 6, 2008 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Subject: FDA Draft Guidance for Industry, Residual Solvents in Drug
More informationCONTRACT RESEARCH SERVICES
1537 NW 65th Avenue Plantation, FL 33313 USA Phone: (954) 321-8988 Fax: (954) 321-9778 info@receptopharm.com www.receptopharm.com ReceptoPharm has installed the pathways to develop, produce and supply
More informationA NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry BIOPHARMACEUTICAL TECHNOLOGY TRANSFER Instructor Loh Kean Chong Date
More informationBULGARIAN ASSOCIATION FOR DRUG INFORMATION (BADI)
1 BULGARIAN ASSOCIATION FOR DRUG INFORMATION (BADI) With the kind support from the Medical University - Sofia, organizes its regular autumn course on Pharmaceutical Regulations on the following topics
More information21 CFR Part 11 Compliance for SaaS/Cloud Applications
21 CFR Part 11 Compliance for SaaS/Cloud Applications *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! This highly interactive two-day course uses real life examples and explores
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationGMP meets Regulatory Affairs
GMP meets Regulatory Affairs Applying for and maintaining marketing authorisations: What you need to know from a GMP perspective Speakers: Marieke van Dalen Aspen Oss B.V., The Netherlands Dr Rainer Gnibl
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 5 GLP Auditing 6 Pharmacovigilance Auditing 6 Vendor/Supplier Auditing 7
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationCAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS
CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS How TOPRA can support you as you drive your regulatory career forward ABOUT TOPRA TOPRA (The Organisation for Professionals in Regulatory Affairs)
More informationReduce costs for compliance with data integrity: 21 CFR Part 11, SaaS/Cloud, EU GDPR
Reduce costs for compliance with data integrity: 21 CFR Part 11, SaaS/Cloud, EU GDPR *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! This highly interactive two-day course uses
More informationANMAT Order No 5260/2008
ANMAT Order No 5260/2008 HAVING REGARD TO Laws Nos 16.463, 17.818, 19.303; Decrees Nos 9763/64, 150/92, 1890/92, 177/93; Joint Resolutions Nos 268/92 (M.S. and A.S.) and 470/92 (M.E. and O.S.P.) and No
More informationQuality Assessment & GMP Similarities & Differences
Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences
More informationICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment
ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment Thomas Schultz, Ph.D. Director, Regulatory Sciences Johnson & Johnson September 12, 2007 Presentation
More informationA.1 Contents file 4 to 5 A.1 (1)
Contents file 4 to 5 Contents file 4 to 5 A Information Contents file 4 to 5 A.2 Index file 4 to 5 A.3 List of Abbreviations A.4 Glossary A.5 Adress-Register A.6 References B Japanese Regulations B.1 MHW
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationISPE NORDIC COP CLEAN UTILITIES SEPTEMBER TUUSULA FINLAND. Timo Kuosmanen STERIS Finn-Aqua
ISPE NORDIC COP CLEAN UTILITIES SEPTEMBER 7 2016 TUUSULA FINLAND Timo Kuosmanen STERIS Finn-Aqua Timo_Kuosmanen@steris.com AUDIT TRAIL IN CRITICAL UTILITIES MONITORING CURRENT TRENDS CONTENTS BACKGROUND
More informationIDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES
IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312
More informationStrategies for IND Filing Success: Chemistry, Manufacturing and Controls
Strategies for IND Filing Success: Chemistry, Manufacturing and Controls October 21, 2016 Presented by: Sharon Ayd, Ph.D., MBA Chief Scientific Officer and SVP, Pharmaceuticals document contains proprietary
More informationNUSAGE PharmEng. Pharmaceutical and Biotechnology Training Program GMP FACILITY DESIGN WITH GOOD ENGINEERING PRACTICE
GMP FACILITY DESIGN WITH GOOD ENGINEERING PRACTICE NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry GMP FACILITY DESIGN
More informationGMP In-house Training
Your benefits: Customised to fit your company s requirements - cost-effective and flexible! GMP In-house Training for the Pharmaceutical, API and Medical Device Industry We offer practice-oriented GMP
More informationComputerized System Validation Part of the Pharmaceutical and Biotechnology Training Courses
National University of Singapore Academy of GxP Excellence (NUSAGE) and PharmEng Technology Presents Computerized System Validation Part of the Pharmaceutical and Biotechnology Training Courses Instructor
More informationCurriculum Vitae of KHANDKER MOHAMMAD KHALID
Curriculum Vitae of KHANDKER MOHAMMAD KHALID 2339, Campus Club Court Phone No. : +18139987412 Apt No. 204 E-Mail : khalid_duph1@yahoo.om Tampa, FL 33612 kmkhalid@mail.usf.edu Academic Qualifications University/College
More informationAnnex 14 WHO guidelines for drafting a site master file 136
World Health Organization WHO Technical Report Series, No.961, 2011 Annex 14 WHO guidelines for drafting a site master file 136 1. Introduction 2. Purpose 3. Scope 4. Content of site master fi le Appendix
More informationEurope s new approach to assurance of API quality and its implications for manufacturers and producing countries
Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries IPA / EDQM / WHO Mumbai Conference 28 September 2012 Dr Florence Benoit-Guyod, EDQM Inspector,
More informationICH Quality Implementation Working Group POINTS TO CONSIDER
ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements
More informationSampling Strategies - Is the N rule always the Best?
Sampling Strategies - Is the N rule always the Best? Comprehensive and Effective Sampling of Finished Pharmaceutical Products, APIs, Excipients, Package Components and Medical Devices SPEAKERS: Dr Raphael
More informationNUSAGE PharmEng. Pharmaceutical and Biotechnology Training Program FUNDAMENTALS OF MEDICAL DEVICE REGULATORY AFFAIRS
FUNDAMENTALS OF MEDICAL DEVICE REGULATORY AFFAIRS NUSAGE PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry FUNDAMENTALS OF MEDICAL
More informationControl Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationA NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program
A NUSAGE-PharmEng Pharmaceutical and Biotechnology Training Program Shaping Human Capital for Challenges in the Pharmaceutical Industry CLEANROOM DESIGN FOR ASEPTIC PROCESSING Instructor Loh Kean Chong
More informationPG Diploma in Pharmaceutical Quality Assurance onwards- CCII Page 1 of 5
PG Diploma in Pharmaceutical Quality Assurance 2014-15 onwards- CCII Page 1 of 5 BHARATHIAR UNIVERSITY: COIMBATORE-641 046 CENTRE FPR COLLABORATION OF INDUSTRY AND INSTITUTION(CCII) POST GRATUATE DIPLOMA
More informationProposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>
Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding Ravi Ravichandran, Ph.D. Steve Zigler, Ph.D. February 21, 2011 Agenda Rationale for the
More informationThe APIC Audit Programme Version 5, July 2017
The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationWhile the recognition
Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change
More informationOECD and EPA GLP Differences
OECD and EPA GLP Differences Annette Leslie RQAP-GLP Du Pont Pioneer Ankeny Iowa I conduct studies in the US, so Why do I care about oecd regulations? Disclaimer: I cannot cover all the differences in
More information